EVH’s Director, WILLIAMS FRANK J, sellss 110,000 shares.

0
5

Evolent Health Inc.’s filing revealed that its Director WILLIAMS FRANK J unloaded Company’s shares for reported $3.23 million on Nov 01. In the deal valued at $29.32 per share,110,000 shares were sold. As a result of this transaction, WILLIAMS FRANK J now holds 626,479 shares worth roughly $ 14.06 million.


Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored


Then, Scott Cheryl sold 3,100 shares, generating $113,956 in total proceeds. Upon selling the shares at $36.76, the Director now owns 51,104 shares.

Before that, WILLIAMS FRANK J sold 50,000 shares. Evolent Health Inc. shares valued at $1,860,500 were divested by the Director at a price of $37.21 per share. As a result of the transaction, WILLIAMS FRANK J now holds 752,434 shares, worth roughly $16.89 million.

Truist initiated its Evolent Health Inc. [EVH] rating to a Hold in a research note published on Monday, November 01, 2022; the price target was $33. PT values the company’s stock at a premium of 31.97 to its Monday closing price. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late July with a ‘”an Outperform”‘ rating. Guggenheim began covering EVH with “Buy” recommendation on March 30, 2022. JP Morgan revised its rating on November 18, 2021. It rated EVH as “an Overweight” which previously was an “a Neutral”.

Price Performance Review of EVH

On Monday, Evolent Health Inc. [NYSE:EVH] saw its stock fall -7.88% to $22.45. On the same session, the stock had its day’s lowest price of $22.40, but rose to a high of $24.46. Over the last five days, the stock has lost -29.42%. Evolent Health Inc. shares have fallen nearly -18.87% since the year began. Nevertheless, the stocks have fallen -24.36% over the past one year. While a 52-week high of $39.78 was reached on 09/15/22, a 52-week low of $21.36 was recorded on 01/24/22. SMA at 50 days reached $34.25, while 200 days put it at $30.80. A total of 1.97 million shares were traded, compared to the trading of 1.32 million shares in the previous session.

Levels Of Support And Resistance For EVH Stock

The 24-hour chart illustrates a support level at 21.75, which if violated will result in even more drops to 21.04. On the upside, there is a resistance level at 23.81. A further resistance level may holdings at 25.16. The Relative Strength Index (RSI) on the 14-day chart is 19.26, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -5.43, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 99.52%. Stochastics %K at 4.72% indicates the stock is a buying.

How much short interest is there in Evolent Health Inc.?

A steep rise in short interest was recorded in Evolent Health Inc. stocks on Jul 14, 2022, growing by 0.3 million shares to a total of 8.42 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 8.12 million shares. There was a rise of 3.56%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 10.04% of the overall stock float, the days-to-cover ratio (short ratio) rose to 7.79.

Evolent Health Inc. [EVH] – Who Are The Largest Shareholders?

In filings from The Vanguard Group, Inc., it is revealed that the company now owns 7,650,868 shares, or roughly 8.35% of the outstanding EVH shares. In other words, the investor’s shares have risen by 142,695 from its previous 13-F filing of 7508173.0. Over the last quarter, Fidelity Management & Research Co purchased 499,219 shares of Evolent Health Inc., while JPMorgan Investment Management, I bought -20,458 shares. At present, Granahan Investment Management, L is holding 3,181,532 shares valued at $114.31 million. Engaged Capital LLC owned 2,810,978 shares of the company at the time of its most recent 13F filing, worth $101.0 million.

According to FactSet, Evolent Health Inc.’s share price will average $42.88 in the next year, based on opinions of analysts polled by the firm. This is up nearly 80.55 percent from its previous closing price of $24.37. Analysts expect Evolent Health Inc. stock to reach the higher price of $52.00, while the lowest price estimate is $33.00. However, 9 analysts have rated EVH stock as a Buy in their predictions for 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here